Paratek Pharmaceuticals, Inc. Contracts & Agreements
246 Contracts & Agreements
- Business Finance (48 contracts)
- Business Operations (45)
- Human Resources (66)
- Intellectual Property (20)
- Mergers & Acquisitions (2)
- Real Estate (18)
- Uncategorized (47)
- First Supplemental Indenture, dated as of September 21, 2023, by and between the Company and U.S. Bank Trust Company, National Association (f/k/a U.S. Bank National Association),... (Filed With SEC on September 21, 2023)
- Agreement and Plan of Merger, dated as of June 6, 2023, by and among the Company, Resistance Acquisition, Inc. and Resistance Merger Sub, Inc (Filed With SEC on June 7, 2023)
- Form of Contingent Value Rights Agreement to be entered into between Resistance Acquisition, Inc. and a Rights Agent (Filed With SEC on June 7, 2023)
- Form of Voting Agreement to be entered into between Parent and the Management Stockholders (Filed With SEC on June 7, 2023)
- Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended (Filed With SEC on March 14, 2022)
- Non-Employee Director Compensation Policy (Filed With SEC on March 14, 2022)
- Fifth Amendment to the Amended and Restated Manufacturing and Services Agreement, by and between the Company and CIPAN - Companhia Industrial Produtora de Antibiticos, S.A., dated... (Filed With SEC on March 14, 2022)
- Amendment No. 4 to the Product Agreement, by and between the Company and Patheon UK Limited, dated as of November 17, 2021 (Filed With SEC on March 14, 2022)
- Supply Agreement, dated July 14, 2021, between Paratek Pharmaceuticals, Inc. and CARBOGEN AMCIS AG (Filed With SEC on November 8, 2021)
- Modification of Contract No. 2, dated July 29, 2021, between Paratek Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority of the United States... (Filed With SEC on November 8, 2021)
- Modification of Contract No. 3, dated September 23, 2021, between Paratek Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority of the United States... (Filed With SEC on November 8, 2021)
- At-the-Market Sales Agreement, dated May 17, 2021, by and between Paratek Pharmaceuticals, Inc. and BTIG, LLC (Filed With SEC on May 17, 2021)
- Non-Employee Director Compensation Policy (Filed With SEC on March 29, 2021)
- Loan Agreement, dated as of December 31, 2020, by and between R-Bridge Healthcare Cayman AIV, L.P., as Lender, and PRTK SPV2 LLC, as Borrower (Filed With SEC on January 4, 2021)
- Revenue Interest Purchase Agreement, dated as of December 31, 2020, by and between Paratek Pharmaceuticals, Inc., as Seller, and PRTK SPV2 LLC, as Company (Filed With SEC on January 4, 2021)
- Contribution and Servicing Agreement, dated as of December 31, 2020, by and between Paratek Pharmaceuticals, Inc., as Contributor, and PRTK SPV2 LLC, as Company (Filed With SEC on January 4, 2021)
- First Amendment to the Manufacturing and Services Agreement, by and between the Company and Almac Pharma Services Limited, dated as of September 4, 2020 (Filed With SEC on January 4, 2021)
- Second Amendment to the Manufacturing and Services Agreement, by and between the Company and Almac Pharma Services Limited, dated as of January 1, 2021 (Filed With SEC on January 4, 2021)
- Second Amendment to the Amended and Restated Manufacturing and Services Agreement, by and between the Company and CIPAN - Companhia Industrial Produtora de Antibiticos, S.A.,... (Filed With SEC on January 4, 2021)
- Third Amendment to the Amended and Restated Manufacturing and Services Agreement, by and between the Company and CIPAN - Companhia Industrial Produtora de Antibiticos, S.A., dated... (Filed With SEC on January 4, 2021)
- Fourth Amendment to the Amended and Restated Manufacturing and Services Agreement, by and between the Company and CIPAN - Companhia Industrial Produtora de Antibiticos, S.A.,... (Filed With SEC on January 4, 2021)
- First Amendment of Manufacturing and Services Agreement, by and between the Company and Patheon UK Limited, dated as of June 1, 2019 (Filed With SEC on January 4, 2021)
- Second Amendment of Manufacturing and Services Agreement, by and between the Company and Patheon UK Limited, dated as of December 18, 2020 (Filed With SEC on January 4, 2021)
- Amendment No. 2 to the Product Agreement, by and between the Company and Patheon UK Limited, dated as of June 1, 2019 (Filed With SEC on January 4, 2021)
- Amendment No. 3 to the Product Agreement, by and between the Company and Patheon UK Limited, dated as of July 1, 2020 (Filed With SEC on January 4, 2021)
- Warrant Agreement, dated as of August 5, 2020 issued to Hercules Capital, Inc (Filed With SEC on August 10, 2020)
- First Amendment to the 2019 Amended and Restated Loan and Security Agreement, dated August 5, 2020, by and among Paratek Pharmaceuticals, Inc., Paratek Pharma, LLC, certain... (Filed With SEC on August 10, 2020)
- Non-Employee Director Compensation Policy (Filed With SEC on May 11, 2020)
- Description of Securities (Filed With SEC on March 10, 2020)
- Amended and Restated Employee Agreement for Michael F. Bigham effective June 25, 2019 (Filed With SEC on August 6, 2019)
- Amended and Restated Employee Agreement for Evan Loh, MD, effective June 25, 2019 (Filed With SEC on August 6, 2019)
- Amended and Restated Employee Agreement for Adam Woodrow effective June 25, 2019 (Filed With SEC on August 6, 2019)
- At the Market Sales Agreement, dated July 2, 2019, by and among Paratek Pharmaceuticals, Inc., Jefferies LLC, and BTIG, LLC (Filed With SEC on July 2, 2019)
- Amended and Restated Loan and Security Agreement, dated June 27, 2019, by and among Paratek Pharmaceuticals, Inc., Paratek Pharma, LLC, Hercules Technology III and certain other... (Filed With SEC on July 2, 2019)
- Amendment Agreement - Amendment No. 1 to Patheon Product Agreement by and between the Company and Patheon UK Limited dated as of January 1, 2019 (Filed With SEC on May 8, 2019)
- Consulting Agreement dated March 15, 2019 between the Company and Douglas Pagn (Filed With SEC on March 18, 2019)
- First Amendment of Amended and Restated Manufacturing and Services Agreement, by and between the Company and CIPAN Companhia Industrial Produtora de Antibiticos, S.A., dated as... (Filed With SEC on March 6, 2019)
- First Amendment of Outsourcing Agreement, by and between the Company and CARBOGEN AMCIS AG, dated as of December 18, 2018 (Filed With SEC on March 6, 2019)
- 2018 Employee Stock Purchase Plan, as amended (Filed With SEC on November 6, 2018)
- Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended (Filed With SEC on October 18, 2018)
- Revenue Performance Incentive Plan (Filed With SEC on October 4, 2018)
- Form of Award Agreement under the Revenue Performance Incentive Plan (Filed With SEC on October 4, 2018)
- Warrant Agreement, dated August 1, 2018 issued to Hercules Capital, Inc. Form 8-K 001-36066 4.1 June 29, 2017 4.6 Warrant, dated as of April 7, 2014 issued to HBM Healthcare... (Filed With SEC on August 2, 2018)
- Amended and Restated Manufacturing and Services Agreement by and between the Company and CIPAN Companhia Industrial Produtora de Antibiticos, S.A., dated as of April 18, 2018 (Filed With SEC on August 2, 2018)
- Amendment No. 5 to Loan and Security Agreement dated August 1, 2018, by and between Paratek Pharmaceuticals, Inc., Paratek Pharma, LLC, Hercules Technology II, L.P., Hercules... (Filed With SEC on August 2, 2018)
- Paratek Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan (Filed With SEC on June 18, 2018)
- Purchase Agreement, dated as of April 18, 2018, among Paratek Pharmaceuticals, Inc. and the several Initial Purchasers named in Schedule A thereto for whom Merrill Lynch, Pierce,... (Filed With SEC on April 23, 2018)
- Indenture, dated as of April 23, 2018, by and between Paratek Pharmaceuticals, Inc. and U. S. Bank National Association (including the form of the 4.75% Convertible Senior... (Filed With SEC on April 23, 2018)
- Amendment No.4 to the Loan and Security Agreement, as amended, with Hercules Technology II, L.P., Hercules Technology III, L.P. and certain other lenders, and Hercules Technology... (Filed With SEC on April 23, 2018)
- Form of Director Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2015 Equity Incentive Plan (Filed With SEC on March 6, 2018)
- Form of Director Stock Option Grant Notice and Option Agreement under the 2015 Equity Incentive Plan (Filed With SEC on March 6, 2018)
- Non-Employee Director Compensation Policy (Filed With SEC on March 6, 2018)
- Underwriting Agreement, dated January 17, 2018, between Paratek Pharmaceuticals, Inc. and BTIG, LLC (Filed With SEC on January 19, 2018)
- Employment Agreement, as amended, by and between the Company and Michael F. Bigham dated as of August 4, 2017 (Filed With SEC on November 8, 2017)
- Employment Agreement, as amended, by and between the Company and William M. Haskel dated as of August 4, 2017 (Filed With SEC on November 8, 2017)
- Employment Agreement, as amended, by and between the Company and Evan Loh, M.D. dated as of August 4, 2017 (Filed With SEC on November 8, 2017)
- Employment Agreement, as amended, by and between the Company and Douglas W. Pagn dated as of August 4, 2017 (Filed With SEC on November 8, 2017)
- Employment Agreement, as amended, by and between the Company and Adam Woodrow dated as of August 4, 2017 (Filed With SEC on November 8, 2017)
- Form of Leadership Team Restricted Stock Unit Grant Notice and Form of Leadership Team Restricted Stock Unit Award Agreement under the Paratek Pharmaceuticals, Inc. 2015 Equity... (Filed With SEC on August 4, 2017)
- Employment Agreement, as amended, by and between the Company and Michael F. Bigham dated as of June 16, 2017 (Filed With SEC on August 2, 2017)
- Employment Agreement, as amended, by and between the Company and William M. Haskel dated as of June 16, 2017 (Filed With SEC on August 2, 2017)
- Employment Agreement, as amended, by and between the Company and Evan Loh, M.D. dated as of June 16, 2017 (Filed With SEC on August 2, 2017)
- Employment Agreement, as amended, by and between the Company and Douglas W. Pagn dated as of June 16, 2017 (Filed With SEC on August 2, 2017)
- Employment Agreement, as amended, by and between the Company and Adam Woodrow dated as of June 16, 2017 (Filed With SEC on August 2, 2017)
- License and Collaboration Agreement by and between Paratek Bermuda Ltd. and Zai Lab (Shanghai) Co., Ltd., dated April 21, 2017 (Filed With SEC on August 2, 2017)
- Master Manufacturing Service Agreement by and between the Company and Patheon UK Limited dated as of July 28, 2017 and Product Agreement by and between the Company and Patheon UK... (Filed With SEC on August 2, 2017)
- Form of Warrant (Filed With SEC on June 29, 2017)
- Amendment No. 3 to Loan and Security Agreement dated June 27, 2017, by and between Paratek Pharmaceuticals, Inc., Paratek Pharma, LLC, Hercules Technology II, L.P., Hercules... (Filed With SEC on June 29, 2017)
- PARATEK PHARMACEUTICALS, INC. 2017 INDUCEMENT PLAN ADOPTED: June 15, 2017 (Filed With SEC on June 16, 2017)
- Paratek Pharmaceuticals, Inc. Stock Option Grant Notice (2017 Inducement Plan) (Filed With SEC on June 16, 2017)
- Paratek Pharmaceuticals, Inc. Restricted Stock Unit Grant Notice (2017 Inducement Plan) (Filed With SEC on June 16, 2017)
- PARATEK PHARMACEUTICALS, INC. ANNUAL INCENTIVE PLAN (Filed With SEC on June 16, 2017)
- AMENDMENT NO. 10 TO THE TUFTS UNIVERSITY LICENSE AGREEMENT (Filed With SEC on May 4, 2017)
- LEASE (Filed With SEC on May 4, 2017)
- OFFICE LEASE THE HERITAGE ON THE GARDEN BOSTON, MASSACHUSETTS PARATEK PHARMA, LLC. -1- (Filed With SEC on May 4, 2017)
- Paratek Pharmaceuticals, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on March 2, 2017)
- Paratek Pharmaceuticals, Inc. Director Restricted Stock Unit Grant Notice (2015 Equity Incentive Plan) (Filed With SEC on March 2, 2017)
- Paratek Pharmaceuticals, Inc. Director Stock Option Grant Notice (2015 Equity Incentive Plan) (Filed With SEC on March 2, 2017)
- PARATEK PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on March 2, 2017)
- AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENT (Filed With SEC on March 2, 2017)
- OFFICE LEASE THE HERITAGE ON THE GARDEN BOSTON, MASSACHUSETTS PARATEK PHARMA, LLC. (Filed With SEC on March 2, 2017)
- LEASE (Filed With SEC on March 2, 2017)
- THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES... (Filed With SEC on March 2, 2017)
- THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES... (Filed With SEC on March 2, 2017)
- THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES... (Filed With SEC on March 2, 2017)
- Paratek Pharmaceuticals, Inc. Leadership Team Restricted Stock Unit Grant Notice (2015 Equity Incentive Plan) (Filed With SEC on February 8, 2017)
- FORM OF WARRANT AGREEMENT To Purchase Shares of the Common Stock of PARATEK PHARMACEUTICALS, INC. Dated as of ____________ (the Effective Date) (Filed With SEC on December 13, 2016)
- AMENDMENT NO. 2 TO LOAN AND SECURITY AGREEMENT (Filed With SEC on December 13, 2016)
- PARATEK PHARMACEUTICALS, INC. (aDelaware corporation) 4,250,000 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on June 22, 2016)
- PARATEK PHARMACEUTICALS, INC. (FORMERLY KNOWN AS TRANSCEPT PHARMACEUTICALS, INC. 2006 INCENTIVE AWARD PLAN Amended and Restated Effective as of the Date of the 2010 Annual... (Filed With SEC on March 9, 2016)
- PARATEK PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on March 9, 2016)
- INDEMNIFICATION AGREEMENT (Filed With SEC on March 9, 2016)
- PARATEK PHARMACEUTICALS, INC. Shares of Common Stock (par value$0.001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on October 15, 2015)
- WARRANT AGREEMENT To Purchase Shares of the Common Stock of PARATEK PHARMACEUTICALS, INC. Dated as of _______________ (the Effective Date) (Filed With SEC on October 5, 2015)
- STOCK PURCHASE AGREEMENT (Filed With SEC on October 5, 2015)
- Relocation Expense (Filed With SEC on August 11, 2015)
- Amended and Restated Non-Employee Director Cash Compensation Policy Effective as of January 1, 2015 (Filed With SEC on August 11, 2015)
- PARATEK PHARMACEUTICALS, INC. AMENDMENT NO. 1 TO TAXBENEFIT PRESERVATION PLAN (Filed With SEC on July 24, 2015)
- [remainder of page intentionally left blank] (Filed With SEC on May 15, 2015)
- PARATEK PHARMACEUTICALS, INC. (aDelaware corporation) 2,860,000 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on April 30, 2015)
- ASSIGNMENT, ASSUMPTION, AMENDMENT AND CONSENT 75 Kneeland Street, Lease of 6th Floor (Filed With SEC on April 2, 2015)
- COLLABORATIVE RESEARCH AND LICENSE AGREEMENT between WARNER CHILCOTT COMPANY, INC. and PARATEK PHARMACEUTICALS, INC. July 2, 2007 (Filed With SEC on April 2, 2015)
- TUFTS UNIVERSITY LICENSE AGREEMENT (Filed With SEC on April 2, 2015)
- Exhibit A EMPLOYEE PROPRIETARY INFORMATION, INVENTIONS ASSIGNMENT, NON- COMPETITION ANDNON-SOLICITATION AGREEMENT Exhibit A EMPLOYEE PROPRIETARY INFORMATION, INVENTIONS... (Filed With SEC on April 2, 2015)
- [remainder of page intentionallyleft blank] (Filed With SEC on April 2, 2015)
- [remainder of page intentionally left blank] (Filed With SEC on April 2, 2015)
- WARRANT AGREEMENT To PurchaseShares of the Series C Preferred Stock of TransOral Pharmaceuticals, Inc. Dated as of April 13, 2006 (the Effective Date) (Filed With SEC on April 2, 2015)
- PARATEK PHARMACEUTICALS, INC. WARRANT TO PURCHASE SERIES A PREFERRED STOCK (Filed With SEC on April 2, 2015)
- PARATEK PHARMACEUTICALS, INC. WARRANT TO PURCHASE SERIES A PREFERRED STOCK (Filed With SEC on April 2, 2015)
- PARATEK PHARMACEUTICALS, INC. WARRANT TO PURCHASE SERIES A PREFERRED STOCK (Filed With SEC on April 2, 2015)
- PARATEK PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT AWARD GRANT NOTICE 2006 INCENTIVE AWARD PLAN (Filed With SEC on February 10, 2015)
- PARATEK PHARMACEUTICALS, INC. 2015 INDUCEMENT PLAN ADOPTED: FEBRUARY 4, 2015 (Filed With SEC on February 10, 2015)
- PARATEK PHARMACEUTICALS, INC. 2015 INDUCEMENT PLAN STOCK OPTION GRANT NOTICE (Filed With SEC on February 10, 2015)
- INDEMNIFICATION AGREEMENT (Filed With SEC on October 31, 2014)
- TERMINATION AGREEMENT AND RELEASE (Filed With SEC on October 28, 2014)
- FIFTH AMENDMENT (1003 West Cutting Boulevard, Richmond, California) (Filed With SEC on August 6, 2014)
- SUPPORT AGREEMENT (Filed With SEC on July 1, 2014)
- SUPPORT AGREEMENT (Filed With SEC on July 1, 2014)
- FOURTH AMENDMENT TO LEASE (Filed With SEC on March 14, 2014)
- AMENDED AND RESTATED CHANGE OF CONTROL AND SEVERANCE BENEFITS AGREEMENT (Filed With SEC on March 14, 2014)
- AMENDED AND RESTATED CHANGE OF CONTROL AND SEVERANCE BENEFITS AGREEMENT (Filed With SEC on March 14, 2014)
- AMENDED AND RESTATED CHANGE OF CONTROL AND SEVERANCE BENEFITS AGREEMENT (Filed With SEC on November 7, 2013)
- AMENDED AND RESTATED CHANGE OF CONTROL AND SEVERANCE BENEFITS AGREEMENT (Filed With SEC on November 7, 2013)
- AMENDED AND RESTATED CHANGE OF CONTROL AND SEVERANCE BENEFITS AGREEMENT (Filed With SEC on November 7, 2013)
- AMENDED AND RESTATED CHANGE OF CONTROL AND SEVERANCE BENEFITS AGREEMENT (Filed With SEC on November 7, 2013)
- AMENDED AND RESTATED CHANGE OF CONTROL AND SEVERANCE BENEFITS AGREEMENT (Filed With SEC on November 7, 2013)
- LICENSE AGREEMENT (Filed With SEC on November 7, 2013)
- TRANSCEPT PHARMACEUTICALS, INC. and AMERICAN STOCKTRANSFER & TRUST COMPANY, LLC as Rights Agent Tax Benefit Preservation Plan Dated as of September 13, 2013 TAX BENEFIT... (Filed With SEC on September 13, 2013)
- THIRD AMENDMENT TO LEASE (Filed With SEC on May 9, 2013)
- TRANSCEPT PHARMACEUTICALS, INC. Fourth Amended and Restated Independent Director Equity Compensation Policy Effective April 10, 2013 (Filed With SEC on May 9, 2013)
- TRANSCEPT PHARMACEUTICALS, INC. Third Amended and Restated Independent Director Equity Compensation Policy Effective January 4, 2013 (Filed With SEC on March 12, 2013)
- WARRANT TO PURCHASE STOCK (Filed With SEC on November 19, 2012)
- LOAN AND SECURITY AGREEMENT (Filed With SEC on November 19, 2012)
- INVESTOR RIGHTS AGREEMENT (Filed With SEC on September 27, 2012)
- INVESTOR RIGHTS AGREEMENT (Filed With SEC on September 27, 2012)
- O Y S T E R P O I N T M A R I N A P L A Z A Partial Lease Termination Agreement (Filed With SEC on July 2, 2012)
- Sublease Termination Agreement (Filed With SEC on July 2, 2012)
- CHANGE OF CONTROL AND SEVERANCE BENEFITS AGREEMENT (Filed With SEC on June 26, 2012)
- CHANGE OF CONTROL AND SEVERANCE BENEFITS AGREEMENT (Filed With SEC on June 4, 2012)
- TRANSCEPT PHARMACEUTICALS, INC. (a Delaware corporation) 4,500,000 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on April 26, 2012)
- FIRST AMENDMENT TO UNITED STATES LICENSE AND COLLABORATIONAGREEMENT (Filed With SEC on March 30, 2012)
- TRANSCEPT PHARMACEUTICALS, INC. Second Amended and Restated IndependentDirector Cash Compensation Policy Effective June 2, 2010 (Filed With SEC on March 30, 2011)
- AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (Filed With SEC on May 14, 2010)
- TRANSCEPT PHARMACEUTICALS, INC. TERMINATION AGREEMENT (Filed With SEC on May 14, 2010)
- UNITED STATES LICENSE ANDCOLLABORATION AGREEMENT by and between TRANSCEPT PHARMACEUTICALS, INC. and PURDUE PHARMACEUTICAL PRODUCTS L.P. TABLE OF CONTENTS (Filed With SEC on November 16, 2009)
- Purdue Pharmaceutical Products L.P. One Stamford Forum Stamford, CT 06901 (Filed With SEC on November 16, 2009)
- LP Clover Limited (Filed With SEC on November 16, 2009)
- AMENDMENT #2 TO PATHEON MANUFACTURING SERVICESAGREEMENT (Filed With SEC on November 16, 2009)
- AMENDMENT #1 TO (Filed With SEC on November 16, 2009)
- AMENDMENT #2 TO (Filed With SEC on November 16, 2009)
- FIRST AMENDMENT PLANTEX SUPPLY AGREEMENT (Filed With SEC on November 16, 2009)
- CHANGE OF CONTROL AND SEVERANCE BENEFITS AGREEMENT (Filed With SEC on August 14, 2009)
- CHANGE OF CONTROL AND SEVERANCE BENEFITS AGREEMENT (Filed With SEC on August 14, 2009)
- CHANGE OF CONTROL AND SEVERANCE BENEFITS AGREEMENT (Filed With SEC on August 14, 2009)
- CHANGE OF CONTROL AND SEVERANCE BENEFITS AGREEMENT (Filed With SEC on August 14, 2009)
- CHANGE OF CONTROL AND SEVERANCE BENEFITS AGREEMENT (Filed With SEC on August 14, 2009)
- CHANGE OF CONTROL AND SEVERANCE BENEFITS AGREEMENT (Filed With SEC on August 14, 2009)
- CHANGE OF CONTROL AND SEVERANCE BENEFITS AGREEMENT (Filed With SEC on August 14, 2009)
- CHANGE OF CONTROL AND SEVERANCE BENEFITS AGREEMENT (Filed With SEC on August 14, 2009)
- CHANGE OF CONTROL AND SEVERANCE BENEFITS AGREEMENT (Filed With SEC on August 14, 2009)
- SUBLEASE (Filed With SEC on August 14, 2009)
- TRANSCEPT PHARMACEUTICALS, INC. 2009EMPLOYEE STOCK PURCHASE PLAN ADOPTED BYTHE BOARD OF DIRECTORS: APRIL 3, 2009 APPROVED BY THE STOCKHOLDERS: JUNE 3, 2009 (Filed With SEC on June 9, 2009)
- TRANSCEPT PHARMACEUTICALS, INC. Amended and Restated Independent Director Cash CompensationPolicy (Filed With SEC on May 15, 2009)
- INDEMNIFICATION AGREEMENT (Filed With SEC on April 9, 2009)
- INDEMNIFICATION AGREEMENT (Filed With SEC on April 9, 2009)
- SECOND AMENDMENT TO LEASE (Filed With SEC on March 31, 2009)
- LEASE BETWEEN POINT RICHMOND R&D ASSOCIATES II, LLC, a California limited liability company (LANDLORD) AND TRANSCEPTPHARMACEUTICALS, INC., a Delaware corporation (TENANT) POINT... (Filed With SEC on March 31, 2009)
- CHANGE OF CONTROL AND SEVERANCE BENEFITS AGREEMENT (Filed With SEC on March 31, 2009)
- TRANSCEPTPHARMACEUTICALS, INC. (Filed With SEC on February 5, 2009)
- TRANSORAL PHARMACEUTICALS, INC. (Filed With SEC on February 5, 2009)
- WARRANT AGREEMENT (Filed With SEC on February 5, 2009)
- TRANSCEPT PHARMACEUTICALS, INC. AMENDED AND RESTATED 2002 STOCK OPTION PLAN (Filed With SEC on February 5, 2009)
- TRANSCEPT PHARMACEUTICALS, INC. AMENDED AND RESTATED 2002 STOCK OPTION PLAN (Filed With SEC on February 5, 2009)
- LOAN AND SECURITY AGREEMENT (Filed With SEC on February 5, 2009)
- SECURED PROMISSORY NOTE (Filed With SEC on February 5, 2009)
- LEASE BETWEEN POINT RICHMOND R&D ASSOCIATES, a California limited partnership (LANDLORD) (Filed With SEC on February 5, 2009)
- FIRST AMENDMENT TO LEASE (Filed With SEC on February 5, 2009)
- SUPPLY AGREEMENT between PLANTEX USA INC. 2 University Plaza, Suite 305, Hackensack, NJ 07601 (Plantex) and TRANSORAL PHARMACEUTICALS, INC. 300 Tamal Plaza, Suite 200, Corte... (Filed With SEC on February 5, 2009)
- PACKAGING AND SUPPLY AGREEMENT (Filed With SEC on February 5, 2009)
- Amendment to the Packaging and Supply Agreement dated September 14, 2006 (Filed With SEC on February 5, 2009)
- Manufacturing Services Agreement Between (Filed With SEC on February 5, 2009)
- AMENDMENT #1 TO MANUFACTURING SERVICES AGREEMENT (Filed With SEC on February 5, 2009)
- SUPPLY AND SUBLICENSE AGREEMENT (Filed With SEC on February 5, 2009)
- MANUFACTURING AND SUPPLY AGREEMENT (Filed With SEC on February 5, 2009)
- PACKAGING AND SUPPLY AGREEMENT (Filed With SEC on February 5, 2009)
- SUPPLY AND LICENSE AGREEMENT (Filed With SEC on February 5, 2009)
- AMENDMENT #1 TO SUPPLY AND LICENSE AGREEMENT (Filed With SEC on February 5, 2009)
- SUPPLY AGREEMENT (Filed With SEC on February 5, 2009)
- AMENDMENT TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (Filed With SEC on December 30, 2008)
- ANDREORGANIZATION among: NOVACEA, INC., a Delaware corporation; (Filed With SEC on September 4, 2008)
- VOTING AGREEMENT (Filed With SEC on September 4, 2008)
- VOTING AGREEMENT (Filed With SEC on September 4, 2008)
- OYSTER POINT MARINA PLAZA Office Lease (Filed With SEC on March 17, 2008)
- AMENDMENT TO EXECUTIVE SEVERANCE BENEFIT AGREEMENT (Filed With SEC on December 18, 2007)
- AMENDMENT TO EXECUTIVE SEVERANCE BENEFIT AGREEMENT (Filed With SEC on December 18, 2007)
- EXECUTIVE SEVERANCE BENEFITS AGREEMENT (Filed With SEC on November 27, 2007)
- NOVACEA, INC. September 19, 2007 (Filed With SEC on September 24, 2007)
- AMENDED AND RESTATED SUPPLY AGREEMENT (Filed With SEC on August 14, 2007)
- AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT BETWEEN OHSU AND (Filed With SEC on August 14, 2007)
- AMENDED AND RESTATED LICENSE AGREEMENT (Filed With SEC on August 14, 2007)
- LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT (Filed With SEC on June 1, 2007)
- NOVACEA, INC. COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on June 1, 2007)
- NOVACEA, INC. Amended and Restated Independent Director Cash Compensation Policy (Filed With SEC on May 15, 2007)
- 19 April 2007 (1) BTG INTERNATIONAL LIMITED (Filed With SEC on May 15, 2007)
- ASSIGNMENT by and between KUDOS PHARMACEUTICALS LIMITED and (Filed With SEC on May 15, 2007)
- NOVACEA, INC. 2006 INCENTIVE AWARD PLAN (Filed With SEC on April 2, 2007)
- NOVACEA, INC. Amended and Restated Independent Director Cash Compensation Policy (Filed With SEC on April 2, 2007)
- THIRD AMENDMENT TO SUPPLY AGREEMENT (Filed With SEC on April 2, 2007)
- Novacea, Inc. (Filed With SEC on December 22, 2006)
- GENERAL RELEASE AND SEPARATION AGREEMENT (Filed With SEC on December 18, 2006)
- Shares (Filed With SEC on May 2, 2006)
- INDEMNIFICATION AGREEMENT (Filed With SEC on May 2, 2006)
- LICENSE AGREEMENT (Filed With SEC on May 2, 2006)
- PATENT AND KNOW-HOW LICENSE AGREEMENT Between (Filed With SEC on May 2, 2006)
- SUPPLY AGREEMENT (Filed With SEC on May 2, 2006)
- NOVACEA, INC. (Filed With SEC on May 2, 2006)
- NOVACEA, INC. 2006 INCENTIVE AWARD PLAN (Filed With SEC on April 14, 2006)
- EXECUTIVE SEVERANCE BENEFITS AGREEMENT (Filed With SEC on April 14, 2006)
- EXECUTIVE SEVERANCE BENEFITS AGREEMENT (Filed With SEC on April 14, 2006)
- EXECUTIVE SEVERANCE BENEFITS AGREEMENT (Filed With SEC on April 14, 2006)
- EXECUTIVE SEVERANCE BENEFITS AGREEMENT (Filed With SEC on April 14, 2006)
- EXECUTIVE SEVERANCE BENEFITS AGREEMENT (Filed With SEC on April 14, 2006)
- EXECUTIVE SEVERANCE BENEFITS AGREEMENT (Filed With SEC on April 14, 2006)
- NOVACEA, INC. (Filed With SEC on April 14, 2006)
- EXCLUSIVE LICENSE AGREEMENT BETWEEN OHSU AND D-NOVO THERAPEUTICS, INC. (Filed With SEC on March 28, 2006)
- LICENSE AGREEMENT (Filed With SEC on March 28, 2006)
- /s/ Amar Singh (Filed With SEC on March 28, 2006)
- SECOND AMENDMENT TO SUPPLY AGREEMENT (Filed With SEC on March 28, 2006)
- ADDENDUM No. 1 (Filed With SEC on March 28, 2006)
- NOVACEA, INC. (Filed With SEC on February 10, 2006)
- 2001 STOCK OPTION PLAN OF NOVACEA, INC. (Filed With SEC on February 10, 2006)
- EXCLUSIVE LICENSE AGREEMENT BETWEEN OHSU AND D-NOVO THERAPEUTICS, INC. (Filed With SEC on February 10, 2006)
- LICENSE AGREEMENT (Filed With SEC on February 10, 2006)
- LICENSE AGREEMENT (Filed With SEC on February 10, 2006)
- PATENT AND KNOW-HOW LICENSE AGREEMENT Between (Filed With SEC on February 10, 2006)
- SUPPLY AGREEMENT (Filed With SEC on February 10, 2006)
- TRADEMARK LICENSE AGREEMENT between PIERRE FABRE MEDICAMENT S.A. and NOVACEA, Inc. Dated (Filed With SEC on February 10, 2006)
- AGREEMENT (Filed With SEC on February 10, 2006)
- AGREEMENT (Filed With SEC on February 10, 2006)
- SUPPLY AGREEMENT (Filed With SEC on February 10, 2006)
- FIRST AMENDMENT TO SUPPLY AGREEMENT (Filed With SEC on February 10, 2006)
- OFFICE LEASE (Filed With SEC on February 10, 2006)
- AMENDED AND RESTATED FIRST AMENDMENT TO LEASE (Filed With SEC on February 10, 2006)
- SECOND AMENDMENT TO LEASE (Filed With SEC on February 10, 2006)
- Novacea 601 Gateway Blvd., Suite 800 So. San Francisco, CA 94080 ###-###-#### (Filed With SEC on February 10, 2006)
- [Company Letter Head] (Filed With SEC on February 10, 2006)